Login to Your Account

SHANGHAI – In its fourth in-licensing deal this year, Yabao Pharmaceutical Co. Ltd., of Suzhou, China, signed a deal with the prestigious MRC Tech, a UK-based nonprofit, to co-develop therapeutics for the treatment of Parkinson's disease.

Prosensa Holding NV hopped off the rollercoaster it's been traveling on for more than a year by agreeing to a cash acquisition deal with Biomarin Pharmaceutical Inc. worth about $680 million up front, with another $160 million to come in two near-term regulatory milestones.

Genome engineering firm Transposagen Biopharmaceuticals Inc. will seek to segue into a long-planned run at drug development as it joins the increasingly crowded race to develop chimeric antigen receptor T cells through a research collaboration and global license deal with Janssen Biotech Inc.

More DEALS AND M&A Headlines

Cast Your Vote

Has biotech’s bubble burst?: